Navigation Links
Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Date:1/28/2008

TORONTO, Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced it has completed its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate. The Pre-IND meeting focused on development plans for the drug, including manufacturing details, preclinical pharmacology and toxicology data, and the proposed plans for the Phase I clinical program.

"The completion of our pre-IND meeting with the FDA is an important milestone for the Company and demonstrates the significant progress we have made with our lead CD44 Cancer Stem Cell Program and our ability to advance drug candidates towards human clinical trials," said Dr. David Young, President and Chief Executive Officer. "We are pleased with the outcome of this meeting and will continue to prepare for our IND submission with the intention of initiating human clinical trials this year."

Concurrently, ARIUS announced the promotion of Susan Hahn, PhD, formerly Director of Development, to the position of Vice President of Development. "Dr. Hahn has been instrumental in leading the development of our antibody programs that we are taking to the clinic," said Dr. Young. "In her new role, Dr. Hahn will continue to focus on meeting ARIUS' development milestones as we move each of our lead drug candidates towards human clinical trials."

The CD44 Cancer Stem Cell program was generated using ARIUS' proprietary FunctionFIRST(TM) technology, which selects antibodies based on their ability to kill cancer cells. Pre-clinical data from a dose-ranging pilot toxicology study in non-human primate models demonstrated no dose-limiting toxic effects at doses up
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. ARIUS to present at Chinese Global Financial Forum
7. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
8. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
9. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
10. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
11. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... September 30, 2014 Proove Biosciences ... is excited to announce a new genetic test built ... Proove Pain Perception Test will provide physicians with ... why pain tolerance levels are stratified between individuals. With ... whether a person has a genetic predisposition that will ...
(Date:9/30/2014)... BUDAPEST, Hungary , September 30, 2014 /PRNewswire/ ... libraries and intuitive browsing of chemistry in documents ... providing chemistry software solutions and consulting services for ... extract chemical information and generate Markush structures from ... securing an organizations intellectual property, however generating and ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... focusing on commercializing market-relevant biohealth innovations and increasing access ... , announced today that venture capitalist, Tania Fernandez ... strategic advisor. Dr. Fernandez will be a member of ... which will provide up to $50 million in seed ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... 11, 2011 Novavax, Inc. (Nasdaq: NVAX ... by the Tech Council of Maryland (TCM), the largest ... communities of Maryland.  Novavax was recognized as the firm ... community and for its presence and leadership in Maryland. ...
... May 11, 2011 Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, ... will present at two upcoming conferences. Mr. ... Solutions Conference as part of the "Biofuels" panel discussion ...
... Ill., May 11, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced the completion of an ... Partners and Latterell Venture Partners.  Druid BioVentures, Genesys Capital, ... in the round.  Naurex will use the proceeds from ...
Cached Biology Technology:Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland 2Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Naurex Completes $18 Million Series A Financing 2Naurex Completes $18 Million Series A Financing 3Naurex Completes $18 Million Series A Financing 4Naurex Completes $18 Million Series A Financing 5Naurex Completes $18 Million Series A Financing 6Naurex Completes $18 Million Series A Financing 7
(Date:9/30/2014)... your doctor to know what goes wrong with your muscles ... to know what "normal" actually is. That,s where a new ... FASEB Journal comes in. In the ... set of molecules that can help scientists "see" which genes ... more, they found never-before-detected gene activity and that men have ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... DC Monday, September 29: Between 1970 and ... fish around the globe dropped 52 percent, says ... World Wildlife Fund (WWF). This biodiversity loss occurs ... resource use of high-income countries. , In addition ... report,s data point to other warning signs about ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2
... part of the Genome Canada Large-Scale Applied Research Project ... to 16 projects across the country, the researchers in ... with the aim of identifying genes or proteins for ... target cancers and other diseases. The first project, ...
... - New research from the University of Calgary,s Faculty ... diagnosis using an iPhone application with the same accuracy ... technology can be particularly useful in rural medical settings. ... neurologists, regardless of where the physicians and patients are ...
... has revealed how infection by a parasitic fungus dramatically changes ... leonardi ), causing them to become zombie-like and to die ... fungus. The multinational research team studied ants living high up ... research will be published in the BioMed Central open-access journal ...
Cached Biology News:OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3iPhone can diagnose stroke: study 2Zombie ants have fungus on the brain, new research reveals 2
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: